In last trading session, Fulcrum Therapeutics Inc (NASDAQ:FULC) saw 1.17 million shares changing hands with its beta currently measuring 2.28. Company’s recent per share price level of $6.60 trading at $0.97 or 17.23% at ring of the bell on the day assigns it a market valuation of $356.26M. That closing price of FULC’s stock is at a discount of -53.48% from its 52-week high price of $10.13 and is indicating a premium of 64.85% from its 52-week low price of $2.32.
For Fulcrum Therapeutics Inc (FULC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.29. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Upright in the green during last session for gaining 17.23%, in the last five days FULC remained trading in the green while hitting it’s week-highest on Thursday, 05/15/25 when the stock touched $6.60 price level, adding 0.45% to its value on the day. Fulcrum Therapeutics Inc’s shares saw a change of 40.43% in year-to-date performance and have moved 22.00% in past 5-day. Fulcrum Therapeutics Inc (NASDAQ:FULC) showed a performance of 117.11% in past 30-days.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a fall of -65.0% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would jump 69.7% in reaching the projected high whereas dropping to the targeted low would mean a gain of 69.7% for stock’s current value.
Fulcrum Therapeutics Inc (FULC) estimates and forecasts
This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 54.59% during past 5 years.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at FULC for having 11.61 million shares of worth $71.98 million. And as of 2024-06-30, it was holding 18.6636 of the company’s outstanding shares.
The second largest institutional holder is RTW INVESTMENTS, LP, which was holding about 5.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.3979 of outstanding shares, having a total worth of $36.24 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 1.85 shares of worth $12.22 million or 3.43% of the total outstanding shares. The later fund manager was in possession of 1.48 shares on Mar 31, 2025, making its stake of worth around $9.76 million in the company or a holder of 2.74% of company’s stock.
